ZA202002080B - Glp-2 analogs and peptibodies for administration before, during or after surgery - Google Patents
Glp-2 analogs and peptibodies for administration before, during or after surgeryInfo
- Publication number
- ZA202002080B ZA202002080B ZA2020/02080A ZA202002080A ZA202002080B ZA 202002080 B ZA202002080 B ZA 202002080B ZA 2020/02080 A ZA2020/02080 A ZA 2020/02080A ZA 202002080 A ZA202002080 A ZA 202002080A ZA 202002080 B ZA202002080 B ZA 202002080B
- Authority
- ZA
- South Africa
- Prior art keywords
- glp
- analogs
- surgery
- small intestine
- during
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582055P | 2017-11-06 | 2017-11-06 | |
| PCT/US2018/059175 WO2019090209A1 (en) | 2017-11-06 | 2018-11-05 | Glp-2 analogs and peptibodies for administration before during, or after surgery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202002080B true ZA202002080B (en) | 2025-11-26 |
Family
ID=66332372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/02080A ZA202002080B (en) | 2017-11-06 | 2020-05-04 | Glp-2 analogs and peptibodies for administration before, during or after surgery |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11660328B2 (enExample) |
| EP (1) | EP3706774A4 (enExample) |
| JP (2) | JP7296958B2 (enExample) |
| KR (1) | KR102825098B1 (enExample) |
| CN (1) | CN111629745A (enExample) |
| AR (1) | AR113835A1 (enExample) |
| AU (1) | AU2018360744A1 (enExample) |
| BR (1) | BR112020008936A2 (enExample) |
| CA (1) | CA3079523A1 (enExample) |
| IL (1) | IL274098B2 (enExample) |
| MX (1) | MX2020004620A (enExample) |
| TW (1) | TW201922279A (enExample) |
| WO (1) | WO2019090209A1 (enExample) |
| ZA (1) | ZA202002080B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7249492B2 (ja) * | 2017-08-22 | 2023-03-31 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | Ｇｌｐ－２融合ポリペプチドならびに消化管の状態を処置および予防するための使用 |
| US20210355187A1 (en) * | 2018-10-24 | 2021-11-18 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| US20230129788A1 (en) * | 2020-03-30 | 2023-04-27 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| CA3178994A1 (en) | 2020-05-19 | 2021-11-25 | Iyassu Sebhat | Ampk activators |
| JP2023531726A (ja) | 2020-06-26 | 2023-07-25 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| WO2021263040A1 (en) * | 2020-06-26 | 2021-12-30 | Shire-Nps Pharmaceuticals, Inc. | Stable peptibody formulations |
| CN115636876A (zh) * | 2021-07-20 | 2023-01-24 | 重庆派金生物科技有限公司 | 胰高血糖素样肽-2突变体的定向化学偶联物及其应用 |
| CN117467025B (zh) * | 2023-12-28 | 2024-04-16 | 上海鼎新基因科技有限公司 | 一种抗vegf和补体双功能融合蛋白及其应用 |
| WO2025181330A1 (en) * | 2024-02-29 | 2025-09-04 | Vectivbio Ag | Dosage regimens for glucagon-like peptide 2 (glp-2) analogs |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1809318B1 (en) * | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
| US20090175795A1 (en) | 2005-07-29 | 2009-07-09 | Amprotein Corporation | Chimeric therapeutic agents |
| WO2007067828A2 (en) * | 2005-10-24 | 2007-06-14 | Centocor, Inc. | Glp-2 mimetibodies, polypeptides, compositions, methods and uses |
| JP5290177B2 (ja) * | 2006-08-31 | 2013-09-18 | セントカー・インコーポレーテツド | Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途 |
| JP2008247789A (ja) * | 2007-03-30 | 2008-10-16 | Kissei Pharmaceut Co Ltd | クローン病に伴う腸管狭窄の進展抑制用医薬組成物 |
| PT2755675T (pt) | 2011-09-12 | 2018-10-11 | Amunix Operating Inc | Composições de péptido semelhante a glucagão-2 e métodos para produzir e utilizar as mesmas |
| US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| CN104540850B (zh) | 2012-05-03 | 2018-05-18 | 西兰制药公司 | 胰高血糖素样肽2(glp-2)类似物 |
| CN106029087A (zh) * | 2013-12-20 | 2016-10-12 | 印第安纳大学研究及科技有限公司 | 脂质化肠降血糖素受体配体人免疫球蛋白fc区融合多肽 |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
-
2018
- 2018-11-05 KR KR1020207013387A patent/KR102825098B1/ko active Active
- 2018-11-05 EP EP18872377.9A patent/EP3706774A4/en active Pending
- 2018-11-05 MX MX2020004620A patent/MX2020004620A/es unknown
- 2018-11-05 CN CN201880071791.3A patent/CN111629745A/zh active Pending
- 2018-11-05 JP JP2020526107A patent/JP7296958B2/ja active Active
- 2018-11-05 AU AU2018360744A patent/AU2018360744A1/en not_active Abandoned
- 2018-11-05 WO PCT/US2018/059175 patent/WO2019090209A1/en not_active Ceased
- 2018-11-05 BR BR112020008936-2A patent/BR112020008936A2/pt unknown
- 2018-11-05 CA CA3079523A patent/CA3079523A1/en active Pending
- 2018-11-05 US US16/761,606 patent/US11660328B2/en active Active
- 2018-11-05 IL IL274098A patent/IL274098B2/en unknown
- 2018-11-06 TW TW107139266A patent/TW201922279A/zh unknown
- 2018-11-06 AR ARP180103232A patent/AR113835A1/es unknown
-
2020
- 2020-05-04 ZA ZA2020/02080A patent/ZA202002080B/en unknown
-
2023
- 2023-06-13 JP JP2023096692A patent/JP7752152B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111629745A (zh) | 2020-09-04 |
| WO2019090209A1 (en) | 2019-05-09 |
| MX2020004620A (es) | 2020-10-12 |
| EP3706774A1 (en) | 2020-09-16 |
| CA3079523A1 (en) | 2019-05-09 |
| KR102825098B1 (ko) | 2025-06-26 |
| AU2018360744A1 (en) | 2020-05-07 |
| KR20200085763A (ko) | 2020-07-15 |
| RU2020118172A (ru) | 2021-12-08 |
| US20210169986A1 (en) | 2021-06-10 |
| TW201922279A (zh) | 2019-06-16 |
| IL274098B2 (en) | 2024-12-01 |
| JP2023107883A (ja) | 2023-08-03 |
| JP7752152B2 (ja) | 2025-10-09 |
| IL274098B1 (en) | 2024-08-01 |
| US11660328B2 (en) | 2023-05-30 |
| JP7296958B2 (ja) | 2023-06-23 |
| BR112020008936A2 (pt) | 2020-10-20 |
| EP3706774A4 (en) | 2021-09-08 |
| JP2021502389A (ja) | 2021-01-28 |
| IL274098A (en) | 2020-06-30 |
| AR113835A1 (es) | 2020-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202002080B (en) | Glp-2 analogs and peptibodies for administration before, during or after surgery | |
| MX2019012081A (es) | Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso. | |
| BR112021015799A2 (pt) | Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado | |
| MX2020001598A (es) | Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5). | |
| EA201890817A1 (ru) | Кристаллические формы бета-никотинамида мононуклеотида | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
| EA202091400A1 (ru) | Производные пиррола в качестве ингибиторов асс | |
| PH12015500683A1 (en) | Formula fortifier | |
| EP3946085A4 (en) | SURGICAL SYSTEM AND METHOD FOR STABILIZATION AND FIXATION OF FRACTURES, JOINTS AND RECONSTRUCTIONS | |
| WO2015023553A3 (en) | Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules | |
| WO2019108592A3 (en) | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy | |
| MX2020001574A (es) | Sistemas y metodos para el control de la enfermedad de necrosis hepatopancreatica aguda. | |
| WO2020026212A3 (en) | Methods of preparing personalized blood vessels | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| MX2017003112A (es) | Procedimiento para preparar una composicion de consome que puede ser bombeada. | |
| BR112017019431A2 (pt) | material de implante de compósito | |
| MX2017000878A (es) | Peptidos marinos y nucleotidos de pescado, composiciones y sus usos para reducir la glucosa en la sangre. | |
| EA201700032A1 (ru) | Универсальный кардиоплегический раствор (варианты) | |
| BR112018016180A2 (pt) | bebida proteica asséptica e método de preparação | |
| EA201270016A1 (ru) | Галогенированные алифатические карбоновые кислоты, их олигомеры и/или полимеры и их применение для девитализации внешних и внутренних новообразований | |
| MX2020002606A (es) | Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso. | |
| MX2018001041A (es) | Concentrado que contiene alprostadil. | |
| MX367120B (es) | Pinzas para reparación percutánea del tendón de aquiles por mínima invasión. | |
| AU2014101423A4 (en) | Abalone blood flavoured ethyl alcohol. |